OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial

Cephalalgia : an International Journal of Headache
H-C DienerPREEMPT 2 Chronic Migraine Study Group

Abstract

This is the second of a pair of studies designed to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX) for prophylaxis of headaches in adults with chronic migraine. PREEMPT 2 was a phase 3 study, with a 24-week, double-blind, placebo-controlled phase, followed by a 32-week, open-label phase. Subjects were randomized (1:1) to injections of onabotulinumtoxinA (155U-195U; n = 347) or placebo (n = 358) every 12 weeks for two cycles. The primary efficacy endpoint was mean change in headache days per 28 days from baseline to weeks 21-24 post-treatment. OnabotulinumtoxinA was statistically significantly superior to placebo for the primary endpoint, frequency of headache days per 28 days relative to baseline (-9.0 onabotulinumtoxinA/-6.7 placebo, p < .001). OnabotulinumtoxinA was significantly favoured in all secondary endpoint comparisons. OnabotulinumtoxinA was safe and well tolerated, with few treatment-related adverse events. Few patients (3.5% onabotulinumtoxinA/1.4% placebo) discontinued due to adverse events. The results of PREEMPT 2 demonstrate that onabotulinumtoxinA is effective for prophylaxis of headache in adults with chronic migraine. Repeated onabotulinumtoxinA treatments were safe and well tolerated.

Associated Clinical Trials

References

Jan 1, 1987·Movement Disorders : Official Journal of the Movement Disorder Society·M F BrinR E Lovelace
Aug 18, 2000·Journal of Pain and Symptom Management·J WisselW Poewe
Feb 7, 2003·The Clinical Journal of Pain·Brian J Freund, Marvin Schwartz
Mar 7, 2003·Pain·Michel Lantéri-MinetAnne-Françoise Gaudin
Jul 23, 2003·Neurology·Richard B Lipton, Marcelo E Bigal
Sep 27, 2003·Cephalalgia : an International Journal of Headache·M SilvestriniL Provinciali
Dec 4, 2003·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·M KosinskiS Tepper
Dec 25, 2003·Neurology·Paul J SpiraUNKNOWN Australian Gabapentin Chronic Daily Headache Group
Jul 21, 2004·Lancet Neurology·Hans-Christoph Diener, Volker Limmroth
Dec 23, 2004·Headache·A I ScherR B Lipton
Sep 24, 2005·Mayo Clinic Proceedings·Stephen D SilbersteinUNKNOWN BoNTA-039 Study Group
Jan 13, 2006·The New England Journal of Medicine·David W Dodick
Mar 25, 2006·Cephalalgia : an International Journal of Headache·M E BigalR B Lipton
May 12, 2006·Cephalalgia : an International Journal of Headache·UNKNOWN Headache Classification CommitteeT J Steiner
May 26, 2006·Expert Opinion on Pharmacotherapy·Sheena Aurora
Nov 23, 2006·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M NaumannM Relja
Feb 16, 2007·Headache·Stephen D SilbersteinUNKNOWN Topiramate Chronic Migraine Study Group
Apr 20, 2007·Cephalalgia : an International Journal of Headache·H-C DienerUNKNOWN TOPMAT-MIG-201(TOP-CHROME) Study Group
May 1, 2007·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Jason C ColeMarcia F T Rupnow
Feb 26, 2008·Cephalalgia : an International Journal of Headache·S SilbersteinUNKNOWN Task Force of the International Headache Society Clinical Trials Subcommittee
Jun 12, 2008·Annals of Neurology·Danièle RanouxD Bouhassira
Aug 30, 2008·Cephalalgia : an International Journal of Headache·H-C DienerD W Dodick
Sep 12, 2008·The Neurologist·Allison Brashear
Dec 2, 2008·Nature Clinical Practice. Neurology·Bahman Jabbari
Sep 8, 2009·Cephalalgia : an International Journal of Headache·S K AuroraC B Rudra
Feb 19, 2010·Journal of Neurology, Neurosurgery, and Psychiatry·D C BuseR B Lipton
Jul 22, 2010·Cephalalgia : an International Journal of Headache·S K AuroraUNKNOWN PREEMPT 1 Chronic Migraine Study Group

❮ Previous
Next ❯

Citations

Jun 7, 2012·HNO·D Dressler
Dec 18, 2013·Der Nervenarzt·H C DienerK Rabe
May 6, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·P BarbantiL Fofi
May 6, 2011·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Licia Grazzi, G Bussone
Jun 1, 2012·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Piero BarbantiLuisa Fofi
May 25, 2013·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Cinzia Finocchi, Erica Viani
Jun 29, 2011·The Journal of Headache and Pain·Peer Carsten Tfelt-Hansen
Jul 17, 2012·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Regina Rendas-BaumSepideh F Varon
Oct 1, 2010·Internal and Emergency Medicine·Andrea NegroPaolo Martelletti
Oct 1, 2010·Internal and Emergency Medicine·Pierangelo GeppettiSilvia Benemei
Nov 17, 2010·Current Pain and Headache Reports·Hans-Christoph DienerDavid Dodick
Feb 12, 2011·Current Pain and Headache Reports·Frederick R Taylor
May 7, 2011·Current Pain and Headache Reports·Robert Gerwin
Nov 16, 2011·Current Pain and Headache Reports·Zaza KatsaravaRichard B Lipton
Dec 18, 2013·Current Pain and Headache Reports·Michel Lanteri-Minet
Nov 26, 2010·Current Treatment Options in Neurology·James R Couch
Nov 15, 2012·Current Treatment Options in Neurology·Elliott Schulman, Brian E McGeeney
Oct 18, 2013·Current Treatment Options in Neurology·Niranjan N Singh, Pradeep Sahota
Mar 27, 2012·Translational Behavioral Medicine·Gregory Lieberman, Magdalena R Naylor
Aug 9, 2013·CNS Drugs·Joel R Saper, Arnaldo Neves Da Silva
Dec 10, 2013·CNS Drugs·Jan Hoffmann, Peter J Goadsby
Feb 15, 2012·Nature Reviews. Neurology·Hans-Christoph DienerStephen D Silberstein
Apr 2, 2013·Plastic and Reconstructive Surgery·Michelle LeeBahman Guyuron
Feb 15, 2012·Journal of Neuro-ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society·Kathleen B Digre, K C Brennan
Mar 2, 2012·Neurology·S D SilbersteinUNKNOWN Chronic Migraine Treatment Trial Research Group
Jan 26, 2012·Neuropsychiatric Disease and Treatment·Carrie E Robertson, Ivan Garza
Jul 13, 2012·CNS Drugs·Katherine A Lyseng-Williamson, James E Frampton
Oct 2, 2012·Annals of Indian Academy of Neurology·Fayyaz AhmedModar Khalil
Jul 1, 2012·Pain Management·Mari Bozoghlanian, Sridhar V Vasudevan
May 29, 2014·Nature Reviews. Neurology·Michael Bjørn Russell
May 29, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Maurizio Cavallini
Jul 18, 2014·Drugs·Kayi Chan, Antoinette MaassenVanDenBrink
Sep 23, 2014·Current Treatment Options in Neurology·Amy R Tso, Peter J Goadsby
Jun 12, 2012·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Tamara PringsheimUNKNOWN Canadian Headache Society Prophylactic Guidelines Development Group
Dec 17, 2014·Pain Management·Brian E Cairns, Parisa Gazerani
Apr 7, 2015·Expert Opinion on Therapeutic Patents·Christopher D KaneSina Bavari
Oct 1, 2011·Expert Review of Neurotherapeutics·Jan Hoffmann
Sep 8, 2010·Expert Review of Neurotherapeutics·Kenneth J Mack

❮ Previous
Next ❯

Methods Mentioned

BETA
pregnancy
contraception

Clinical Trials Mentioned

NCT00168428

Software Mentioned

SAS
PREEMPT
REsearch Evaluating Migraine PREEMPT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.